A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

Clinical trial NCT05306574 · TERMINATED

Trial details

NCT number: NCT05306574
Sponsor: Vor Biopharma
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Systemic Lupus Erythematosus

Start date: 2022-06-20
Primary completion: 2025-01-06
Enrollment: 91

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.